Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Report Date: March 28, 2024
Reporting Period: Fourth quarter and fiscal year ended December 31, 2023.
Context: The filing serves to announce the release of financial results for the specified period via a press release (Exhibit 99.1). The company is designated as an emerging growth company.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed in the text of this Form 8-K. The document solely references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the press release by reference but does not include direct management commentary, guidance, or outlook within the 8-K text itself.
Risks and Contingencies: No specific risks or contingencies are disclosed in this document. The filing includes a standard disclaimer stating that the information shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q4 and full-year 2023 financial figures (revenue, net loss, cash position).
- Verify the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's emerging growth company election and any related accounting transitions.